中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2019-09-12

Henlius and KG Bio Announce a Collaboration for Henlius Novel Anti-PD-1 mAb HLX10 in the Asia Pacific Region
2019-09-07

The Confirmatory Phase 3 Study Results of First China-Manufactured Trastuzumab Biosimilar, HLX02, will be Presented at Both CSCO and ESMO This Year
2019-08-30

2019 ESMO Henlius Abstract Release
2019-08-20

Monoclonal Antibody HLX10 in Patients with Metastatic MSI-H/dMMR Solid Tumors
2019-08-14

First Patient Dosed in Global Phase 3 Clinical Trial of HLX10 in Combination with Chemotherapy in Patients with Metastatic Squamous NSCLC
2019-08-02

Henlius Innovative Anti-c-MET Monoclonal Antibody HLX55 Received IND Application Acceptance Notification from NMPA
2019-07-31

Henlius Innovative Anti-HER2 Monoclonal Antibody HLX22 Have Dosed First Patient for Its Phase 1 Study
2019-07-12

Henlius Novel Anti-PD-1 Antibody HLX10 Received Clinical Trial Approval in Taiwan for the Treatment of Hepatitis B
2019-07-04

Henlius Has Completed the Phase 3 Study of Its Adalimumab Injection HLX03